Recommendation of the President – Opdivo (nivolumab)
On 24 October, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 115/2024 on the evaluation of the drug Opdivo (nivolumab) under the drug program “Treatment of patients with melanoma of the skin or mucous membranes (ICD-10: C43)”